Binding molecules for human factor VIII and factor VIII-like proteins

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9156883
APP PUB NO 20140221611A1
SERIAL NO

13966852

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

It is an object of the present invention to provide novel binding molecules for factor VIII and factor VIII-like proteins. Preferred binding molecules of the present invention exhibit not only distinct characteristics for binding of the target factor VIII polypeptides but also specific and desirable characteristics for release (elution) of the target polypeptides. Especially preferred binding molecules according to the invention are short polypeptide sequences, characterized by a stable loop structure.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • DYAX CORP.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Booth, James E Andover, US 8 169
Deetz, Jeffrey S Melrose, US 9 69
Kelley, Brian D Medford, US 15 291
Potter, M Daniel Acton, US 13 118
Yu, Jinan Acton, US 7 37

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 13, 2027
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00